Open a Trading and Demat Account

Open a demat and trading account with the largest broking house in India. Angel Broking offers online trading account for share trading in Indian stock market. Trade in Stocks, F&O, IPO, Mutual Funds, Commodities, Currency Trading and avail of Investment Advisory and Portfolio Management Services.

Wednesday, July 27, 2011

Stock Market Update on Cadila Healthcare for 1QFY2012

Stock Market Update on Cadila Healthcare for 1QFY2012 with a Buy recommendation and a Target Price of `1,053. (12 months)

For 1QFY2012, Cadila Healthcare (Cadila) reported results that were mostly in-line with our expectations, except on the operating front, which reported lower-than-expected performance. Management has re-affirmed its guidance of US$3bn by FY2015–16. The stock is trading at 24.7x FY2012E and 18.1x FY2013E earnings. We maintain Buy with a revised target price of `1,053.
Results in-line, except on the operating front: For 1QFY2012, Cadila reported net sales of `1,174cr, up 11.2% yoy, higher than our estimates of `1,280cr, driven by the domestic formulation sales and CRAMs JV. On the domestic front, net sales grew by 9% yoy to `436cr (`398.2cr). Gross margin for the quarter declined to 69.1% (69.1%). OPM also declined to 19.6% (20.7%) during the quarter, majorly due to the increase in employee expenses and R&D expenses, which rose by 26.5% and 34.2%, respectively. Adjusted net profit increased by 17.7% yoy to `187.4cr (`159.2cr), higher than our estimates of `179cr. However, reported net profit came in at `234.3cr, registering growth of 15.1% yoy, aided by lower interest expenses and higher other income (of which `44.6cr was contributed by the licensing income from Abbott).           
Outlook and valuation: We expect Cadila’s net sales to post a 20.5% CAGR to `6,478cr and EPS to report a 24.8% CAGR to `52.6 over FY2011–13E. We maintain Buy on the stock with a revised target price of `1,053.

No comments: